Journal of Neurology

, Volume 260, Issue 6, pp 1675–1677 | Cite as

Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient

  • E. Piscolla
  • B. Hakiki
  • L. Pastò
  • L. Razzolini
  • E. Portaccio
  • M. P. Amato
Letter to the Editors

Notes

Conflicts of interest

The study was not funded. Dr. Piscolla has nothing to disclose. Dr. Hakiki receives research support from Merck Serono, Novartis and Teva. Dr. Pastò has nothing to disclose. Dr. Razzolini has received research support from Novartis. Dr. Portaccio serves on a scientific advisory board for Biogen-Idec, Merck Serono and Bayer, received honoraria for speaking from Biogen-Idec and Teva, and receives research support from Merck Serono, Biogen-Idec, Bayer Schering and Sanofi Aventis. Dr. Amato serves on scientific advisory boards for Biogen-Idec, Merck Serono, Bayer Schering and Sanofi Aventis and receives research support and honoraria for speaking from Biogen-Idec, Merck Serono, Bayer Schering and Sanofi Aventis.

Ethical standard

The patient was fully informed and agreed upon the publication of the report in accordance with the ethical standards laid down in the 1964 Helsinki declaration and its amendments.

References

  1. 1.
    Havla JB, Pellkofer HL, Meinl I et al (2012) Rebound of disease activity after withdrawal of Fingolimod (FTY720) treatment. Arch Neurol 69(2):262–264PubMedCrossRefGoogle Scholar
  2. 2.
    Hakiki B, Portaccio E, Giannini M et al (2012) Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler 18(11):1636–1639PubMedCrossRefGoogle Scholar
  3. 3.
    Ghezzi A, Rocca MA, Baroncini D et al (2013) Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol 260(1):327–329PubMedCrossRefGoogle Scholar
  4. 4.
    De Vera A, Kappos L, Zhang-Auberson L et al (2010) Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Mult Scler 16(supplement 10):S 295Google Scholar
  5. 5.
    O’Connor PW, Goodman A, Kappos L et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858–1865PubMedCrossRefGoogle Scholar
  6. 6.
    Vellinga MM, Castelijns JA, Barkhof F et al (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13):1150–1151PubMedGoogle Scholar
  7. 7.
    Martinelli V, Cocco E, Capra R et al (2011) Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 77(21):1887–1895PubMedCrossRefGoogle Scholar
  8. 8.
    Awad A, Stüve O (2009) Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord 2(6):50–61PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • E. Piscolla
    • 1
  • B. Hakiki
    • 1
  • L. Pastò
    • 1
  • L. Razzolini
    • 1
  • E. Portaccio
    • 1
  • M. P. Amato
    • 1
  1. 1.Department of NeurologyUniversity of FlorenceFlorenceItaly

Personalised recommendations